Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Inclusion Criteria: * Participant is informed of the investigational nature of this study and has given written, witnessed informed consent in accordance with institutional, local, and national guidelines * Males or females ≥ 18 and ≤ 80 years of age; pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice a highly effective method of birth control for at least 2 weeks prior to study start, and must be willing to continue practicing birth control for at least 4 weeks after the last dose of study drug. A highly effective method of birth control is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence (only acceptable if practiced as a life-style and not acceptable if one who is sexually active practices abstinence only for the duration of study) or vasectomized partner * Participants with histologically confirmed solid tumor malignancy or lymphoma who are scheduled to receive at least 9 weeks of cyclic myelosuppressive chemotherapy while on study * Hemoglobin value of ≥ 8 and \< 11 g/dL within 1 week prior to administration of study drug. * ECOG Performance Status of 0-2 * One reticulocyte hemoglobin content (CHr) \> 29 picograms within 4 weeks prior to study drug administration. * One transferrin saturation ≥ 15% within 4 weeks prior to study drug administration. * One serum or red cell folate level above the lower limit of normal within 4 weeks prior to study drug administration * One vitamin B12 level above the lower limit of normal within 4 weeks prior to study drug administration * One absolute neutrophil count ≥ 1.0 x 10\^9/L within 1 week prior to administration of study drug * One platelet count ≥ 75 x 10\^9/L within 1 week prior to administration of study drug * Life expectancy \> 6 months. Exclusion Criteria: * Treatment with any erythropoiesis stimulating agent (ESA) in the past 90 days * History of failure to respond to ESA treatment * Known antibodies to other ESAs or history of pure red cell aplasia (PRCA) * Acute or chronic leukemia, myelodysplastic syndrome (MDS), or multiple myeloma * Any previous or planned radiotherapy to more than 50% of either the pelvis or spine * Known intolerance to parenteral iron supplementation * Red blood cell transfusion within 4 weeks prior to study drug administration * Known hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types, etc.) * Known hemolysis * History of pulmonary embolism or deep venous thrombosis (DVT) in the previous 2 years or current therapeutic doses of anticoagulants * Known blood loss as a cause of anemia * Uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 times the upper limit of normal; AST or ALT \> 5 times the upper limit of normal if liver metastases are present. * Creatinine \> 175 micromoles per liter (µmol/L) * History of bone marrow or peripheral blood cell transplantation * Pyrexia/fever of ≥ 39 °C within 48 hours prior to study drug administration * Poorly controlled hypertension, per the Investigator's judgment, within 4 weeks prior to study drug administration (e.g., systolic ≥ 170 mm Hg or diastolic ≥ 100 mm Hg on repeat readings) * Epileptic seizure in the 6 months prior to study drug administration * Advanced chronic congestive heart failure - New York Heart Association Class IV * High likelihood of early withdrawal or interruption of the study * Anticipated elective surgery during the study period * History of multiple drug allergies * Exposure to any investigational agent within 1 month prior to administration of study drug or planned receipt during the study period.